Nikozipix (Cytisinicline)

Cytisinicline, the active ingredient in Nikozipix, is a nicotinic acetylcholine receptor partial agonist presented as an oral tablet for oral use. It treats nicotine dependence and assists adult smokers who wish to quit by reducing cravings and withdrawal symptoms.

GNH USA supplies Nikozipix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Customers benefit from consistent batch release, comprehensive documentation, and responsive technical support throughout the supply chain.

Nikozipix, a nicotinic acetylcholine receptor partial agonist, is indicated for smoking cessation.

- Smoking cessation: Reduces nicotine cravings and withdrawal symptoms, supporting adults who wish to quit smoking.

The most frequently reported adverse reactions with Nikozipix are generally mild and transient.

Common Side Effects: - Nausea - Headache - Insomnia - Abnormal dreams - Dizziness - Gastrointestinal discomfort

Serious or Rare Side Effects: - Mood changes (depression, suicidal ideation) - Severe allergic reaction (anaphylaxis) - Cardiovascular events (tachycardia, hypertension) - Seizures

Before prescribing Nikozipix, clinicians should consider several safety precautions.

- Assess cardiovascular status: evaluate patients for uncontrolled hypertension or recent cardiac events. - Monitor for mood changes: watch for signs of depression or suicidal thoughts during treatment. - Avoid use in severe hepatic impairment: adjust therapy or consider alternative agents. - Do not combine with other nicotine replacement therapies without medical guidance. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Nikozipix may interact with other medicines; some combinations require avoidance while others need monitoring.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - CYP2A6 inhibitors: may increase plasma concentrations of cytisinicline. - Other nicotinic receptor agonists (e.g., nicotine patches): additive stimulation and heightened side‑effects.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs): monitor for increased nausea or insomnia. - Antihypertensive agents: observe blood pressure for possible alterations. - Antiepileptic drugs: potential for reduced seizure threshold.